Status:
UNKNOWN
The Therapy Effect of Azathioprine Initial or 14 Weeks After Combined With Infliximab on CD
Lead Sponsor:
Sixth Affiliated Hospital, Sun Yat-sen University
Conditions:
Crohn Disease
Eligibility:
All Genders
14-60 years
Phase:
NA
Brief Summary
This study aim to identify the therapeutic effect of azathioprine during infliximab(IFX) treatment in Crohn's disease (CD).Half of patients will receive azathioprine and infliximab combination therapy...
Detailed Description
Anti-tumor necrosis factor agents were widely used for many years and were proved to be most reliable drugs in Crohn's disease (CD). About one-third of the patients would develop a secondary lost of r...
Eligibility Criteria
Inclusion
- \- CD patients need infliximab and azathioprine combination therapy
Exclusion
- \- patients had lost response to infliximab or azathioprine previously patients intolerable to infliximab or azathioprine patients need to use 5-Aminosalicylates(5-ASA) patients had participated to other clinical study in two months
Key Trial Info
Start Date :
June 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2019
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT03393247
Start Date
June 1 2017
End Date
July 1 2019
Last Update
January 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China, 510000